European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Cite this article
Serum adiponectin in relation to endometrial cancer and endometrial hyperplasia with atypia in obese women
1 Department of Gynecological Surgery and Oncology of Adults and Adolescents, Pomeranian Medical University of Szczecin (Poland)
Eur. J. Gynaecol. Oncol. 2008, 29(6), 594–597;
Published: 10 December 2008
Objectives: The aim of this work was to compare concentrations of adiponectin in the serum of obese women with endometrial cancer, endometrial hyperplasia with atypia, and normal endometrium. Methods: We enrolled 105 obese women treated at the Department of Gynecological Surgery and Oncology of Adults and Adolescents. The patients were allocated to groups depending on the histological diagnosis (R - endometrial cancer, P - polyps, K - normal endometrium). We subdivided group R depending on the stage and grade of cancer. Results: Significantly lower concentrations of adiponectin were found in patients with endometrial cancer (mean 15.28 μg/mL) as compared with polyps (29.94 μg/ml, p < 0.001) or normal endometrium (22.7 μg/mL, p < 0.05). Stage of cancer had no significant effect on the adiponectin level. When cancer grade was compared, lower levels of adiponectin were observed in patients with G3 (12.86 μg/ml) than G1 (19.04 μg/mL, p < 0.05). Conclusion: Reduced levels of adiponectin may represent an independent risk factor for endometrial cancer